STOCKHOLM--(BUSINESS WIRE)--Regulatory News: “Our commitment to improving access to high quality cancer treatment and management goes beyond selling products”
Elekta (STO:EKTAB) has won a major tender where the Health Department of the People’s Liberation Army (PLA) is expanding its capacity to treat cancer.
Cancer is one of the leading causes of death in China, according to the Earth Policy Institute, and with an aging population, the number of cancer patients is forecasted to grow significantly in the coming years. The PLA, which manages the military hospitals, is addressing the challenge presented by the high incidence and mortality of cancer by awarding a public tender to Elekta for the purchase of cancer management solutions.
Elekta will deliver a comprehensive range of clinical solutions, including Leksell Gamma Knife® as well as linear accelerators and associated software. The total value of the contract amounts to some USD 35 million, making it Elekta’s largest deal ever in China. The order will be booked when all conditions in the tender have been finalized.
Gilbert Wai, Executive Vice President, Region Asia Pacific says: “By partnering with Elekta, the PLA hospitals will help more cancer patients to receive the treatment they need in their battle with cancer. This deal is the latest in many with the PLA, demonstrating the great faith it has in Elekta and our products. It also strengthens Elekta’s number one position in the Chinese market.”
Elekta has been present in China since 1982 and is now the company’s third largest market. “Our commitment to improving access to high quality cancer treatment and management goes beyond selling products,” says Wai. “As a comprehensive solutions partner in China, Elekta helps with clinical implementation as well as education and training services.”
The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 07.30 CET on August 30, 2012.
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,300 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb.
This information was brought to you by Cision http://www.cisionwire.com
Johan Andersson Melbi
Investor Relations Manager
+46 702 100 451